Month: September 2024

Inverse Relationship Between Gold and Bond YieldsBloomberg, U.S. Global InvestorsSan Antonio, TX, Sept. 20, 2024 (GLOBE NEWSWIRE) — U.S. Global Investors, Inc. (NASDAQ: GROW) (“the Company”), a registered investment advisory firm with longstanding experience in global markets and specialized sectors, today announces an update to the stock repurchase program, allowing for the orderly and systematic repurchase of up to $5 million worth of the Company’s common stock between September 13, 2024, and December 31, 2024. This represents 14% of the Company’s market capitalization. This strategic move, combined with the ongoing monthly dividend program, reinforces the Company’s dedication to delivering shareholder value through effective capital allocation and consistent returns. The Company’s Board of Directors (“the Board”) has...

Mullen’s commercial vehicles arrived in Dubai this weekMullen staff also on site in Dubai this week to meet with Volt leadership.First initial shipment included Class 1 and Class 3 EV vans and trucksVolt’s $210M order includes 300 vehicles this year and 3,000 vehicles in 2025.Mullen technical and sales team present in Dubai this week for delivery of first EV vehicles Mullen Automotive, working in conjunction with independent company, VoltiE Group, a Miami, Florida-based EV charging company, are collectively providing EV vehicles and charging equipment to Volt Mobility, a GCC-based vehicle transport and leasing company that offers both commercial electric and gas vehicles and EV charging throughout the Middle East BREA, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) — via IBN — Mullen Automotive, Inc. (NASDAQ: MULN)...

MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that on September 19, 2024 it entered into securities purchase agreements with healthcare focused institutional investors for the issuance and sale of 3,939,394 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering at a purchase price of $1.65 per share. In a concurrent private placement, the Company also agreed to issue to the same investors warrants to purchase up to 3,939,394 shares of common stock. The private placement warrants have an exercise price of $1.84 per...

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver disease Approval follows positive CHMP opinion based on ELATIVE phase III trial data, which demonstrated significant efficacy over placebo and was well-tolerated with an acceptable safety profile This new European approval reinforces Ipsen’s commitment to advancing medical innovations to treat people living with rare cholestatic liver diseasesPARIS, FRANCE, 20 September 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the European Commission has conditionally approved Iqirvo® (elafibranor) 80mg tablets for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA...

Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023 [Link]. The trial investigated the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose of monlunabant compared to placebo on body weight after 16 weeks in 243 people with obesity and metabolic syndrome1. People were equally randomised among the four treatment arms. From a baseline body weight of 110.1 kg, all doses of monlunabant achieved a statistically significant weight loss compared to placebo. After 16 weeks of treatment, people treated with a once-daily 10 mg dose of monlunabant achieved a weight loss of...

Geneva, Switzerland, Sept. 20, 2024 (GLOBE NEWSWIRE) — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI and Post-Quantum technology hardware and software products, today announced the integration of Internet of Payment (IoP) capabilities into its next-generation IoT-enabled semiconductor solutions. This bold step positions SEALSQ at the forefront of a digital revolution, where connected devices transcend their traditional roles, morphing into dynamic commercial hubs capable of secure and autonomous transactions. IoP: Ushering in a New Era of Commerce The Internet of Things (IoT) has transformed everyday objects into smart, connected devices capable of communication and data exchange. Now, with the IoP integration, SEALSQ is taking this...